Cardiol Therapeutics (CRDL) Current Assets (2020 - 2026)

Cardiol Therapeutics has reported Current Assets for 7 years, with the latest figure at $22.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 29.45% year-over-year to $22.8 million; the trailing twelve-month figure through Mar 2026 stood at $22.8 million (up 29.45% YoY), and the FY2025 full-year result was $16.9 million, down 25.66% from the prior year.
• Current Assets for Q1 2026 stood at $22.8 million, up from $16.9 million in the prior quarter.
• The five-year high for Current Assets was $62.2 million in Q1 2022, with the low at $9.3 million in Q3 2025.
• Historically, Current Assets has averaged $29.8 million across 5 years, with a median of $22.8 million in 2026.
• Annual changes were most pronounced in 2022 — Current Assets surged 111.37% — and 2024, when it tumbled 59.99%.
• Cardiol Therapeutics' Current Assets stood at $45.3 million in 2022, then sank by 41.33% to $26.6 million in 2023, then declined by 14.63% to $22.7 million in 2024, then retreated by 25.66% to $16.9 million in 2025, then surged by 35.29% to $22.8 million in 2026.
• The last three Current Assets figures came in at $22.8 million (Q1 2026), $16.9 million (Q4 2025), and $9.3 million (Q3 2025), per Business Quant data.